Annual Report of the HARTMANN GROUP
With a sales increase of 3.5%, the HARTMANN GROUP continued on its previous years’ growth path in fiscal year 2012 and again achieved record sales with EUR 1,758 million. With a situation characterized by spending cuts in the national health care systems, EBIT from regular business increased by 2.5% to EUR 110.2 million despite higher investments in marketing and sales capacities.
In fiscal year 2012, the HARTMANN GROUP took a wide range of measures to ensure sustained growth. Building marketing and sales capacities in connection with the market launch of the new Vivano negative-pressure wound therapy system, but also the further strengthening of the market position in Russia and Australia, led to the planned additional expenses. On the raw material side, there was only a slight easing during the course of 2012.
One-time effects impacted 2012 results. In particular, these included expenses under the Kneipp location concept and modification of the Russian location concept as well as expenses in connection with quality problems with some medical products. EBIT therefore decreased to EUR 87.0 million. The consolidated net income was EUR 55.4 million.
CEO Dr. Rinaldo Riguzzi: “For the current fiscal year, we expect organic sales growth similar to the 2012 growth rate. Considering all relevant factors and provided that there are no unexpected one-time effects, we are confident of further increasing EBIT and consolidated net income."